Want to see IPHA full AI Analyst Report?
IPHA Stock Chart & Stats
$1.78
$0.02(1.14%)
At close: 4:00 PM EDT
$1.78
$0.02(1.14%)
Day’s Range― - ―
52-Week Range$1.17 - $2.71
Previous Close$1.74
Volume2.54K
Average Volume (3M)386.19K
Market Cap
$248.58M
Enterprise Value$150.19
Total Cash (Recent Filing)$34.30M
Total Debt (Recent Filing)$22.56M
Price to Earnings (P/E)―
Beta0.56
Next Earnings
Sep 17, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.55
Shares Outstanding111,718,925
10 Day Avg. Volume29,239
30 Day Avg. Volume386,189
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)-6.14
Price to Sales (P/S)47.79
P/FCF Ratio-3.81
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.67Price Target Upside274.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.54
Revenue Forecast (FY)$24.26M
Bulls Say, Bears Say
Bulls Say
Strategic Sobi PartnershipThe Sobi agreement materially improves lacutamab’s development and commercialization pathway by providing a potential partner-led route into global markets. It also reduces reliance on Innate building a standalone sales infrastructure, subject to closing conditions and clinical success.
Late-Stage Regulatory ProgressFDA clearance and multiple expedited designations strengthen lacutamab’s regulatory positioning in relapsed or refractory Sezary syndrome. These features can support more efficient development and potential accelerated approval, although the program still requires financing and successful trial execution.
Partnered Pipeline OptionalityThe AstraZeneca collaboration provides exposure to multiple late-stage or advancing immunotherapy programs without requiring Innate to fund all development independently. Completed enrollment and substantial remaining milestone pools create durable non-product revenue potential if clinical and commercial targets are achieved.
Bears Say
Limited Cash RunwayThe limited runway creates a near-term financing dependency while several programs approach costly late-stage development. External funding, partnering or royalty financing may be required, increasing dilution, execution and timing risk if capital is not secured promptly.
Negative Equity And Solvency RiskNegative equity indicates that cumulative losses have materially eroded the balance sheet and reduced financial flexibility. Even with lower debt, the position can constrain financing options and heighten the likelihood of future dilution, refinancing pressure or dependence on strategic partners.
High Burn And Weak Revenue BaseInnate lacks recurring product revenue and remains far from self-funding, leaving operations dependent on grants, licensing proceeds and milestone timing. The large gap between income and spending makes earnings volatile and increases the financial consequences of clinical delays or unsuccessful programs.
Innate Pharma News
IPHA FAQ
What was Innate Pharma’s price range in the past 12 months?
Innate Pharma lowest stock price was $1.17 and its highest was $2.71 in the past 12 months.
What is Innate Pharma’s market cap?
Innate Pharma’s market cap is $248.58M.
When is Innate Pharma’s upcoming earnings report date?
Innate Pharma’s upcoming earnings report date is Sep 17, 2026 which is in 23 days.
How were Innate Pharma’s earnings last quarter?
Innate Pharma released its earnings results on Mar 26, 2026. The company reported -$0.358 earnings per share for the quarter, missing the consensus estimate of -$0.142 by -$0.216.
Is Innate Pharma overvalued?
According to Wall Street analysts Innate Pharma’s price is currently Undervalued.
Does Innate Pharma pay dividends?
Innate Pharma does not currently pay dividends.
What is Innate Pharma’s EPS estimate?
Innate Pharma’s EPS estimate is -0.19.
How many shares outstanding does Innate Pharma have?
Innate Pharma has 111,718,925 shares outstanding.
What happened to Innate Pharma’s price movement after its last earnings report?
Innate Pharma reported an EPS of -$0.358 in its last earnings report, missing expectations of -$0.142. Following the earnings report the stock price went down -2.344%.
Which hedge fund is a major shareholder of Innate Pharma?
Currently, no hedge funds are holding shares in IPHA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Innate Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.67 (274.53% Upside)
$6.67 (274.53% Upside)
Blogger Sentiment
Neutral
IPHA Sentiment 50%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
-12.68%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-35.95%
Trailing 12-Months
Company Description
Innate Pharma
Innate Pharma S.A. is a biotechnology firm, founded in 1999 and headquartered in Marseille, France, that specializes in the discovery, development, and market introduction of therapeutic antibodies. The company primarily targets oncology indications across France and internationally, with some programs also addressing inflammatory diseases and viral infections. Its clinical-stage pipeline features several key assets: Lacutamab (IPH4102): An anti-KIR3DL2 antibody undergoing Phase II trials for cutaneous T-cell and peripheral T-cell lymphoma, and also for refractory Sézary syndrome. Monalizumab: An immune checkpoint inhibitor currently in Phase III clinical trials for various advanced solid tumors, including colorectal, lung, and head and neck cancers. Avdoralimab (IPH5401): A monoclonal antibody designed to block C5a binding to C5aR1, which is in Phase II development for COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory conditions. IPH5201: A blocking antibody in Phase I trials, focused on the CD39 immunosuppressive pathway. IPH5301: An anti-CD73 antibody developed to enhance anti-tumor immunity by targeting the immunosuppressive adenosine pathway. IPH6101: An NKp46-based NK cell engager being evaluated for the generation of up to two bispecific NK cell engagers. Innate Pharma also maintains an active preclinical pipeline, including IPH43 (an anti-MICA/B antibody drug conjugate), an Anti-Siglec-9 antibody program, IPH65 (a proprietary tetraspecific antibody), IPH25 (a checkpoint inhibitor), and the IPH62 and IPH64 programs. The company has established strategic licensing and collaboration agreements with major industry players such as AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech, alongside a co-development and license agreement with MedImmune Limited.
IPHA Company Deck
IPHA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call featured multiple meaningful clinical and regulatory milestones (FDA clearance for lacutamab Phase III, completed PACIFIC-9 enrollment, encouraging early IPH4502 data, and high-value partnership milestone potential) and demonstrated cost discipline with lower R&D spend. Offsetting these positives are material near-term financing and execution risks: modest reported revenue (EUR 9M), a high burn rate (EUR 63M operating expenses), and a limited cash runway (EUR 44.8M through Q3 2026) that makes initiation of late-stage programs dependent on partner deals or other financing. Clinical data are promising but still early and need confirmation. Overall, the company shows strong programmatic momentum and partnership upside, but material funding and timing risks balance that optimism.View all IPHA earnings summariesIPHA Stock 12 Month Forecast
Average Price Target
$6.67
▲(274.53% Upside)
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
0.09% Other Institutional Investors
99.91% Public Companies and
Individual Investors